Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Rocket Lab USA Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Rocket Lab USA Inc trades at $53.32 (market cap $41.06B). The key difference: Rocket Lab USA Inc is far larger — about 4.6× Kymera Therapeutics Inc. Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Rocket Lab USA Inc for 29 Days on average.
| KYMR | RKLB | |
|---|---|---|
Market Cap | $8.87B | $41.06B |
Volume | 779,107 | 15,510,966 |
Sector | Health | Industrials |
52-Week High | $127.31 | $150.23 |
52-Week Low | $55.80 | $39.48 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $8.26B | $38.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Rocket Lab (RKLB) trades at $64.22, down 2.27% today, amid bearish technical signals despite strong analyst support. The company recently secured its largest-ever commercial Electron deal with Synspective for 20 launches, boosting its backlog past 100 missions. Financially, RKLB shows robust revenue growth ($602M in 2025, $769M projected for 2026) but remains unprofitable with a net income margin of -21.51%. Valuation metrics appear elevated with a P/S ratio of 48.79.
The outlook balances significant growth potential from a expanding launch backlog against persistent profitability challenges and competitive threats from SpaceX. Analyst consensus is strongly bullish with a $107 price target, but investors face risks from cash burn, execution hurdles, and high valuation multiples. The stock's near-term direction will hinge on Neutron rocket development and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
